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suggest that the cost burden of advanced melanoma to the Medi-
care system is high. Efforts to address the large unmet treatment
need in patients with advanced melanoma may result in cost
savings for Medicare.
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OBJECTIVE: To estimate direct medical costs of breast cancer
(BC) by stage of clinical disease in the Ginecology Hospital of
West Medical Center, Instituto Mexicano del Seguro Social
(IMSS), Guadalajara (GH). METHODS: Clinical data and
resource utilization were obtained individually from medical
records of patients who were breast cancer diagnosed and
received attention at GH between March 2005 and February
2007. This data was retrospectively collected with the following
inclusion criteria: 1) histopathologic-study conﬁrmed BC, 2)
recently diagnosed BC, and 3) absence of any other form of
cancer. Only direct medical costs were considered (from the
GH perspective) using a bottom up approach (medications,
chemotherapy, radiotherapy, hospitalization, laboratory tests
and surgery). Unitary costs were obtained from GH’s Manage-
ment. cost are expressed in USD and adjusted to December 2006.
A discount rate of 3% was used. Tests were applied in order to
deﬁne the censoring mechanism (according to Glick) to deﬁne the
adequate cost analysis method. To compare costs among stage
was use ANOVA. Mean Cost estimation (TMC) determinants
were obtained using a generalized linear Model (GLM).
RESULTS: A total of 160 patients were included, 40 in each stage
(I, II, III, IV), mean age 50 years (11), with a therapy duration
of 29 months (11). 82% of patients showed ductal-inﬁltranting
histologic type carcinoma. TMC per patient during the follow-up
period was ($20,612.00). Chemotherapy was the most costly
resource ($7526.10) followed by the visit to the specialist
and emergency room ($3581.88) and hospitalization costs
($3096.45). GLMxs statistically-signiﬁcant TMC determinants
were stage II, III and IV (p < 0.00), disease progression (p < 0.00)
death (p < 0.00) and age (p < 0.046). CONCLUSION: The direct
cost in medical attention increases with stage, progression of
disease or patient death, stage IV, less age, longer duration of
treatment and disease progression, effectively predicted major
costs.
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OBJECTIVE: To develop an economic analysis of the manage-
ment of pleural effusions in CML patients receiving dasatinib.
METHODS: A cost of treatment analysis was developed using
resource utilization data published for 48 patients with
dasatinib-related pleural effusions at a large cancer center. Costs
were derived from median reimbursements for relevant CPT
codes for outpatient services and medical literature for inpatient
services. The base case analysis assumed 100% incurred two
additional physician visits, two chest x-rays, and a course of
diuretics; 37.5% ECHO; 30% steroids; 24% recurrent effusions;
19% multiple thoracentesis procedures; 4% chest tube; 4%
Denver shunt; and 2% pericardial window. Sensitivity analyses
were conducted for types of procedures used. All costs were
adjusted to 2007 US dollars. RESULTS: Of pleural effusions
reported, 58% involved  25% of one lung volume and were
managed medically costing $750 per episode, including physician
visits, ECHO, chest X-rays and medications. The other 42% of
pleural effusions were more signiﬁcant, involving 26%–>75% of
one lung volume, with half of those patients requiring invasive
procedures. The cost of invasive procedures for inpatient man-
agement of pleural effusions was $10,616 for chest tube, $15,170
with pleural catheter, and $15,344 for pericardial window. The
cost of invasive outpatient management ranged from $713 for
ultrasound thoracentesis to $4598 for pleural catheter. The
average cost of treating a pleural effusion adverse event (includ-
ing all severity levels) ranged from $2062 to >$3000 depending
on whether thoracentesis or placement of pleural catheter was
utilized. Important drivers included recurrent effusions. CON-
CLUSION: This economic analysis based on actually observed
treatment patterns suggests that the management of pleural effu-
sions in CML patients receiving dasatinib is costly and requires
intensive resource utilization. Effective tyrosine kinase inhibitors
with lower rates of pleural effusions may represent clinically
and economically valuable alternatives for imatinib-resistant or
-intolerant CML patients.
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OBJECTIVE: The 2006 American Society of Clinical Oncology
guideline recommends primary prophylaxis (PP) with colony-
stimulating factor (CSF) for elderly patients with diffuse aggres-
sive lymphoma receiving chemotherapy, based on the assumption
of equal survival and studies showing that CSF saved costs by
reducing hospitalization from febrile neutropenia (FN). These
analyses examined only one cycle of chemotherapy, and did not
consider the costs of CSF in subsequent cycles, the strategy of
secondary prophylaxis (SP) or patients’ preferences. This study
examined the cost-effectiveness of PP with SP. METHODS: We
conducted a cost-utility analysis to compare PP with CSF to SP
with CSF for diffuse aggressive lymphoma. We used a Markov
cohort model with a time horizon of 8 cycles of chemotherapy
(i.e. 24 weeks), using a payer’s perspective (Ontario Ministry of
Health). Ontario’s 2006 health economic data was used. The
cost of hospitalization for FN was obtained from Ontario Case
Costing Initiative. Data for efﬁcacies of CSF, probabilities and
utilities were obtained from published literature. Monte Carlo
simulation was conducted. RESULTS: The ICER of PP to SP was
$739,999/QALY. One-way sensitivity analyses (willingness-to-
pay threshold =$100,000) showed that if PP were to be cost-
effective, the cost of hospitalization for FN had to be >$31,138
(2.5 times > base case), the cost of CSF per cycle <$96 (base case
= $1960), the risk of 1st cycle FN >48% (base case = 24%), or
the relative risk reduction of FN with CSF >97% (base case =
41%). Our result was robust to all variables. Second order
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probabilistic sensitivity analysis revealed a 10% probability of PP
being cost-effective over SP at a willingness-to-pay threshold of
$100,000. CONCLUSION: PP is not cost-effective when com-
pared with SP under most assumptions. The costs of CSF and
hospitalization in all cycles should be accounted for in economic
evaluations of CSF.
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OBJECTIVE: The objective of the study is to evaluate cost-
effectiveness of two sequential treatments; with Fulvetsrant
sequence and without Fulvestrant sequence in the treatment of
postmenopausal women with hormone receptor-positive local
advanced or recurrent metastatic breast cancer in Korea.
METHODS: We developed a Markov model which allows
assessments of the two sequential treatments to simulate the
course of patients following each treatment pathway, estimating
health outcomes through a long-term observation. The model
was constructed with data from the literature and expert opin-
ions. Markov health states was consisted of stable/responding,
progressive, and death. The Markov cycle length is 28 days for
each treatment and the cohort size is 1000 patients for each
cohort. This study was analyzed from a societal perspective. All
cost and outcomes were discounted at 5% and currency rate was
applied to U.S. dollars. One-way sensitivity analysis and proba-
bilistic sensitivity analysis were conducted. RESULTS: The base
case results that Cohort A (with Fulvestrant) had 1.037 QALY
and Cohort B (without Fulvestrant) did 0.822 QALY at year 10.
The expected costs results Cohort A spent $2704 more per
patient; Cohort A $16,265 and Cohort B $13,562, respectively.
The resulting ICER Per QALY was $9513 for cohort A to obtain
a quality adjusted life year with respect to Cohort B in the 10-
year model. The results of one-way sensitivity analysis showed
stable; however; that of probability sensitivity analysis resulted
from $15,796 to $16,863 with a range of QALY per person
at 0.6964~0.8704 within 95% CI. CONCLUSION: Ten–year
model of Cohort A in the treatment of postmenopausal women
with hormone receptor-positive local advanced or recurrent
metastatic breast cancer showed better clinical outcomes than
Cohort B.
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OBJECTIVE: In patients with MBC, a common practice in
Europe is to offer ﬁrst line docetaxel or paclitaxel. However, one
important drawback in their use is the potential for dose-limiting
toxicity. An albumin-bound formulation (nab) of paclitaxel
(Abraxane) was recently developed to overcome these safety
drawbacks and to provide additional efﬁcacy. To provide health
economic data, a cost utility analysis comparing nab-paclitaxel
to docetaxel, both as alternatives to paclitaxel was conducted for
the United Kingdom (UK), France, Germany, Italy and Spain.
METHODS: The clinical data were obtained from a meta analy-
sis of randomized trials. Health care resource use for the delivery
of chemotherapy and the management of grade III/IV toxicity
was collected from a survey of European medical oncologists and
from the literature. Using the Time Trade-off technique, utilities
were obtained from 70 female oncology nurses in the UK and
France. RESULTS: Nab-paclitaxel had the most favourable
safety proﬁle with the lowest incidence of grade III/IV neutrope-
nia, febrile neutropenia, anemia, emesis and stomatitis. This
translated to lower overall costs for managing the grade III/IV
toxicity relative to both docetaxel and paclitaxel (e.g. in France;
€286 vs. €966 vs. €422). Using the median number of cycles
administered and the cost of toxicity in each country, the overall
cost for nab-paclitaxel was higher than conventional paclitaxel,
but comparable to docetaxel. Overall, 47 of 70 (67.1%) respon-
dents selected nab-paclitaxel as their preferred choice. As an
alternative to paclitaxel, the incremental cost per QALY gained
was lower for nab-paclitaxel than docetaxel in three of the ﬁve
countries evaluated. CONCLUSION: Given its more favorable
safety proﬁle, improved efﬁcacy and comparable overall cost,
nab-paclitaxel can be considered a preferred option over doc-
etaxel in MBC. As an alternative to paclitaxel, each of the
European health care bodies must decide if the cost per QALY
gained for that country represents good value.
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OBJECTIVE: To compare the cost and utility of adjuvant
Goserelin and adjuvant chemotherapy for premenopausal breast
cancer patients in Taiwan. METHODS: A total of 564 premeno-
pausal breast cancer patients were newly diagnosed since 1993.
Their medical history and vital status were routinely reviewed
and recorded. From July 2007 to December 2007, 105 patients
with stage Ia-IIIa disease who received Goserelin for at least one
year or received at least 6 cycles of chemotherapy as adjuvant
therapy were interviewed to obtain the utility value by standard
gambling (SG) and visual scale (VS) methods. The chemotherapy
included four regimens: CMF (cyclophosphamide, methotrexate,
5-ﬂuorouracil), TE (docetaxel, epirubicin), TEC (docetaxel, epi-
rubicin, cyclophosphamide), and CEF (cyclophosphamide, epi-
rubicin, 5-ﬂuorouracil). The cost of this study was deﬁned as the
total medical cost (surgery, drugs, and all services provided costs)
of standard practices from a payer perspective. The standard
practices of Goserelin and chemotherapy were subcutaneous
injection of 3.6 mg Goserelin every four weeks for two years and
six cycles of CMF, TE, TEC, or CEF, respectively. Survival analy-
sis was conducted by Kaplan-Meier method and weighted by
utility measurements. RESULTS: Survival at 11 years derived
from registry data for patients received Goserelin was better than
patients received chemotherapy (100% vs. 75%). Combining the
survival data with utility score from questionnaires, the utility-
weighted life-years were higher in Goserelin group compared to
chemotherapy group by SG and VS 8.81 vs. 6.83, 8.78 vs. 7.14,
respectively. The cost of Goserelin was lower than that of che-
motherapy and ranged from NT$29,825 to 50,234 (US$918–
1,545) when applying standard body surface of 1.5 m2 and 1.8
m2 about the calculation of chemotherapy doses. CONCLU-
SION: Our data suggest the Goserelin had better survival, higher
utility-weighted life-years, but less cost than chemotherapy in the
adjuvant treatment of premenopausal patients with stage Ia-IIIa
breast cancer in Taiwan.
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